Citigroup’s AgomAb Therapeutics NV AGMB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-9,496
Closed -$123K – 6404
2026
Q2
$123K Buy
+9,496
New +$107K ﹤0.01% 4567

Other funds holding AGMB

Citigroup's AGMB Position: Q3 2026 in Review

Citigroup sold out of AgomAb Therapeutics NV (AGMB) in Q3 2026, closing a stake of 9,496 shares — an estimated $123K sold.

Citigroup first reported a position in AGMB in Q2 2026 and held it in 1 quarter. The position peaked at $123K in Q2 2026. 25 funds tracked by Wall St. Rank hold AGMB as of Q3 2026.

  • Citigroup reported no remaining AgomAb Therapeutics NV position as of Q3 2026 after selling out during the quarter.
  • Citigroup sold 9,496 AgomAb Therapeutics NV shares in Q3 2026, an estimated $123K.
  • Citigroup first reported a position in AgomAb Therapeutics NV in Q2 2026 and held it in 1 quarter.
  • Citigroup's AgomAb Therapeutics NV position peaked at $123K in Q2 2026.
  • 25 funds tracked by Wall St. Rank held AgomAb Therapeutics NV as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.